bluebird bio files for IPO

Gene therapy company bluebird bio Inc. (Cambridge, Mass.) filed to raise up to $86.3 million in an IPO underwritten by JPMorgan; BofA Merrill Lynch; Cowen; Canaccord; and Wedbush. Late this year, the biotech plans to start Phase II/III testing of Lenti-D to treat childhood cerebral adrenoleukodystrophy (ALD). Lenti-D is a hematopoietic stem cell therapy with a lentiviral vector encoding the wild-type gene that encodes the ALD protein. ...